| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Palatin Technologies Inc. | PL9643 - (MELODY-1) | Dry eye disease (DED) | Phase 3 | Data Released | Ophthalmic | Opthalmic |
| Palatin Technologies Inc. | PL9643 - (MELODY-1) | Dry eye disease (DED) | Phase 3 | Data Released | Ophthalmic | Opthalmic |
| Palatin Technologies Inc. | BMT-801 with bremelanotide plus tirzepatide | Obesity | Phase 2 | Data Released | Subcutaneous | Endocrinology |
| Palatin Technologies Inc. | Bremelanotide with Tirzepatide (GLP-1) | Obesity | Phase 2 | Enrollment Conclusion | Subcutaneous injection | Endocrinology |
| Palatin Technologies Inc. | PL8177-205 | Ulcerative colitis (UC) | Phase 2 | Data Released | Oral | Gastroenterology |
| Palatin Technologies Inc. | PL-8177 | Non-infectious uveitis | Phase 2 | Trial Planned | Subcutaneous | Opthalmic |
| Palatin Technologies Inc. | PL-3994 | Heart failure | Phase 2a | Trial Completed | Intravenous | Cardiology |
| Palisade Bio Inc. | LB1148 | Postoperative Return of Bowel Function | Phase 3 | Trial Discontinued | Oral | Gastroenterology |